Silencing PinX1 compromises telomere length maintenance as well as tumorigenicity in telomerase-positive human cancer cells

Cancer Research

Volumn 69, Issue 1, 2009, Pages 75-83

  Zhang, Bin ^a   Yun, Xiu Bai ^a   Hang, Hang Ma ^a   Feng, Feng ^b   Jin, Rui ^a   Zhi, Long Wang ^a   Lin, Jian ^a   Shi, Peng Sun ^a   Yang, Pingxun ^a   Xiao, Xiong Wang ^b   Pei, Tang Huang ^a   Cui, Fen Huang ^a   Peng, Ying ^c   Yang, Chao Chen ^d   Kung, Hsiang Fu ^d   Jun, Jian Huang ^a  

^a BEIJING INSTITUTE OF BIOTECHNOLOGY   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

^c SUN YAT SEN UNIVERSITY   (China)

^d Prince of Wales Hospital   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ETOPOSIDE; NUCLEAR PROTEIN; PROTEIN PINX1; SHORT HAIRPIN RNA; TELOMERASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER CELL; CANCER INHIBITION; CATALYSIS; CELL IMMORTALIZATION; ENZYME ACTIVITY; GENE CONSTRUCT; GENE SILENCING; GROWTH INHIBITION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUCLEOLUS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA GENE; TELOMERE;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; DNA DAMAGE; ETOPOSIDE; GENE SILENCING; HUMANS; MICE; MICE, INBRED BALB C; RNA, SMALL INTERFERING; TELOMERASE; TELOMERE; TELOMERE-BINDING PROTEINS; TRANSFECTION; TUMOR SUPPRESSOR PROTEINS;

EID: 58249097056     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-1393     Document Type: Article

References (32)

1. Harley CB, Futcher AB, Greider CW. Telomeres shorten during ageing of human fibroblasts. Nature 1990;345:458-60.
2. Shay JW, Wright WE. Hayflick, his limit, and cellular ageing. Nat Rev Mol Cell Biol 2000;1:72-6.
3. Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994;266:2011-5.
4. Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA. Creation of human tumour cells with defined genetic elements. Nature 1999;400:464-8.
5. Nakamura TM, Morin GB, Chapman KB, et al. Telomerase catalytic subunit homologs from fission yeast and human. Science 1997;277:955-9.
6. Meyerson M, Counter CM, Eaton EN, et al. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 1997;90:785-95.
7. Lin SY, Elledge SJ. Multiple tumor suppressor pathways negatively regulate telomerase. Cell 2003;113:881-9.
8. Tomlinson RL, Ziegler TD, Supakorndej T, Terns RM, Terns MP. Cell cycle-regulated trafficking of human telomerase to telomeres. Mol Biol Cell 2006;17:955-65.
9. Seimiya H, Sawada H, Muramatsu Y, et al. Involvement of 14-3-3 proteins in nuclear localization of telomerase. EMBO J 2000;19:2652-61.
10. Liu K, Hodes RJ, Weng NP. Cutting edge: telomerase activation in human T lymphocytes does not require increase in telomerase reverse transcriptase (hTERT) protein but is associated with hTERT phosphorylation and nuclear translocation. J Immunol 2001;166:4826-30.
11. Kharbanda S, Kumar V, Dhar S, et al. Regulation of the hTERT telomerase catalytic subunit by the c-Abl tyrosine kinase. Curr Biol 2000;10:568-75.
12. Wong JMY, Kusdra L, Collins K. Subnuclear shuttling of human telomerase induced by transformation and DNA damage. Nat Cell Biol 2002;4:731-6.
13. Lin J, Jin R, Zhang B, et al. Nucleolar localization of hTERT is unrelated to telomerase function in human cells. J Cell Sci 2008;121:2169-76.
14. Zhou XZ, Lu KP. The Pin2/TRF1-interacting protein PinX1 is a potent telomerase inhibitor. Cell 2001;107:347-59.
15. Chang Q, Pang JC, Li J, Hu L, Kong X, Ng HK. Molecular analysis of PinX1 in medulloblastomas. Int J Cancer 2004;109:309-14.
16. Akiyama Y, Maesawa C, Wada K, et al. Human PinX1, a potent telomerase inhibitor, is not involved in human gastrointestinal tract carcinoma. Oncol Rep 2004;11:871-4.
17. Hawkins GA, Chang BL, Zheng SL, et al. Mutational analysis of PINX1 in hereditary prostate cancer. Prostate 2004;60:298-304.
18. Oh BK, Chae KJ, Park C, Park YN. Molecular analysis of PinX1 in human hepatocellular carcinoma. Oncol Rep 2001;12:861-6.
19. Guglielmi B, Werner M. The yeast homolog of human PinX1 is involved in rRNA and small nucleolar RNA maturation, not in telomere elongation inhibition. J Biol Chem 2002;277:35712-9.
20. Colgin LM, Baran K, Baumann P, Cech TR, Reddel RR. Human POT1 facilitates telomere elongation by telomerase. Curr Biol 2003;13:942-6.
21. Wang F, Podell ER, Zaug AJ, et al. The POT1-1 telomere complex is a telomerase processivity factor. Nature 2007;445:506-10.
22. Churikov D, Price CM. Pot1 and cell cycle progression cooperate in telomere length regulation. Nat Struct Mol Biol 2008;15:79-84.
23. Gellert GC, Jackson SR, Dikmen G, Wright WE, Shay JW. Telomerase as a therapeutic target in cancer. Drug Discov Today 2005;2:159-64.
24. Shay JW, Wright WE. Telomerase therapeutics for cancer: challenges and new directions. Nat Rev Drug Discov 2006;5:577-84.
25. Shay JW, Wright WE. Mechanism-based combination telomerase inhibition therapy. Cancer Cell 2005;7:1-2.
26. Chen YC, Lin MC, Yao H, et al. Lentivirus-mediated RNA interference targeting enhancer of zeste homolog 2 inhibits hepatocellular carcinoma growth through down-regulation of stathmin. Hepatology 2007;46:200-8.
27. Kim KC, Jung CS, Choi KH. Overexpression of p73 enhances cisplatin-induced apoptosis in HeLa cells. Arch Pharm Res 2006;29:152-8.
28. Mullen P. PARP cleavage as a means of accessing apoptosis. Methods Mol Med 2004;88:171-81.
29. Baumann P, Cech TR. Pot1, the putative telomere end-binding protein in fission yeast and humans. Science 2001;292:1171-5.
30. de Lange T. Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev 2005;19:2100-10.
31. Saretzki G. Telomerase inhibition as cancer therapy. Cancer Lett 2003;194:209-19.
32. Masutomi K, Yu EY, Khurts S, et al. Telomerase maintains telomere structure in normal human cells. Cell 2003;114:241-53.